- Home
- DKI vs BIVI Comparison
DKI vs BIVI Comparison
Compare DKI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKI
- BIVI
- Stock Information
- Founded
- DKI 2018
- BIVI 2013
- Country
- DKI Hong Kong
- BIVI United States
- Employees
- DKI N/A
- BIVI N/A
- Industry
- DKI
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- DKI
- BIVI Health Care
- Exchange
- DKI Nasdaq
- BIVI Nasdaq
- Market Cap
- DKI 11.9M
- BIVI 14.2M
- IPO Year
- DKI 2025
- BIVI N/A
- Fundamental
- Price
- DKI $0.45
- BIVI $1.38
- Analyst Decision
- DKI
- BIVI
- Analyst Count
- DKI 0
- BIVI 0
- Target Price
- DKI N/A
- BIVI N/A
- AVG Volume (30 Days)
- DKI 220.8K
- BIVI 98.4K
- Earning Date
- DKI 11-28-2025
- BIVI 11-10-2025
- Dividend Yield
- DKI N/A
- BIVI N/A
- EPS Growth
- DKI N/A
- BIVI N/A
- EPS
- DKI 26.19
- BIVI N/A
- Revenue
- DKI $10,204,329.00
- BIVI N/A
- Revenue This Year
- DKI N/A
- BIVI N/A
- Revenue Next Year
- DKI N/A
- BIVI N/A
- P/E Ratio
- DKI $0.02
- BIVI N/A
- Revenue Growth
- DKI 100.46
- BIVI N/A
- 52 Week Low
- DKI $0.43
- BIVI $1.38
- 52 Week High
- DKI $15.00
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- DKI N/A
- BIVI 31.80
- Support Level
- DKI N/A
- BIVI $1.42
- Resistance Level
- DKI N/A
- BIVI $1.66
- Average True Range (ATR)
- DKI 0.00
- BIVI 0.11
- MACD
- DKI 0.00
- BIVI -0.01
- Stochastic Oscillator
- DKI 0.00
- BIVI 5.88
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.